CanSense has raised $2.0M in seed funding. The company uses data analytics and machine learning to boost the performance of its blood test, which is designed to triage patients at high risk of cancer.

Get the full CanSense company profile
Access contacts, investors, buying signals & more
CanSense has raised $2.0M in seed funding. The company uses data analytics and machine learning to boost the performance of its blood test, which is designed to triage patients at high risk of cancer.
Great science needs great partners. Here’s how collaboration is turning an academic prototype into a market-ready diagnostic tool. Colorectal cancer is the fourth most common cancer in the UK, but current diagnostic pathways place an unsustainable demand on the NHS.
To tackle this, CanSense developed an AI-powered liquid biopsy and partnered with us to accelerate its journey to patients. With support from the NIHR Research Support Service (RSS), the Accelerated Surgical Care HealthTech Research Centre, and a £1.16m i4i Product Development Award, CanSense has achieved major milestones: ✨ Validating high-throughput testing with 3,000+ patient samples ✨ Securi

Tallia
Tallia uses a custom retrieval pipeline to help advisors research and draft client deliverables using in-house knowledge, faster than ever before. If you would like to schedule a demo, please get in touch.
$4.5M Seed
today

Nyobolt
Nyobolt is a pioneer in high-power, fast-charging energy solutions that deliver mission-critical uptime for power-demanding industries. Founded in 2019, the company is leading the Instant Power revolution by combining proprietary anode materials, advanced battery cell design, and integrated power electronics to unlock ultrafast charging, exceptional power density, and extended lifecycle. With a robust patent portfolio and a global footprint, Nyobolt unlocks next-gen industrial performance across AI data centers, warehouse robotic automation, and electrified heavy-duty applications. Its solutions reduce total cost of ownership while meeting the performance and reliability demands of an always-on world.
$60.0M Series c
today
Largest funding rounds in Biotechnology on Signalbase right now.
| # | Company | Round | Amount | Date |
|---|---|---|---|---|
| 1 | ![]() Shockwave Medical United States | Unknown | $13.1B | 2y ago |
| 2 | ![]() NeuroEM Therapeutics United States | Unknown |
Companies that recently closed a Seed round.
| # | Company | Round | Amount | Date |
|---|---|---|---|---|
| 1 | ![]() Tallia United Kingdom | Seed | $4.5M | today |
| 2 | ![]() Vitroscope AS | Seed | $7.0M | today |
| 3 |
| $7.2B |
| 2y ago |
| 3 | ![]() GRAIL United States | Unknown | $7.1B | 2y ago |
| 4 | ![]() Illumina United States | Unknown | $7.1B | 2y ago |
| 5 | ![]() RemeGen Biosciences United States | Grant | $5.6B | 9mo ago |
![]() DAMOCLES Diagnostics France |
| Seed |
| $855.0K |
| today |
| 4 | ![]() Rosarium Health United States | Seed | $6.0M | today |
| 5 | ![]() Vitroscope Norway | Seed | $7.0M | today |
Contacts, investors, buying intent signals & tech stack.
Trusted by 200+ sales teams
See who invested in CanSense and reach their contacts directly.
Start free trial
Ondine Biomedical Inc.
Recently received

Rosarium Health
Recently received

Aíma
Recently received